PDR MEMBER LOGIN:
  • PDR Search

    Required field
  • Advertisement
  • FDA Date: 06/13/2011

    FDA Drug Safety Communication for Risperidone (Risperdal) and Ropinirole (Requip)

    Medication Errors Resulting from Confusion Between Risperidone (Risperdal) and Ropinirole (Requip)

    This information reflects FDA's current analysis of data available to FDA concerning this drug. FDA intends to update this sheet when additional information or analyses become available.

    FDA is alerting the public to medication error reports in which patients were given risperidone (Risperdal) instead of ropinirole (Requip) and vice versa. In some cases, patients who took the wrong medication needed to be hospitalized.

    The FDA determined that the factors contributing to the confusion between the two products include:

    1. similarities of both the brand (proprietary) and generic (established) names.

    2. similarities of the container labels and carton packaging.

    3. illegible handwriting on prescriptions.

    4. overlapping product characteristics, such as the drug strengths, dosage forms, and dosing intervals.

    Healthcare professionals are reminded to clearly print or spell out the medication name on prescriptions and make certain their patients know the name of their prescribed medication and their reason for taking it.

    FDA is requesting the manufacturers of Requip (GlaxoSmithKline), Risperdal (Johnson & Johnson), and the generic ropinirole and risperidone products to take the following measures to reduce the potential for confusion between the two products:

    - Use of "tall man" lettering on container labels and carton packaging to present the generic names as risperiDONE and rOPINIRole, which may improve the ability of healthcare professionals to distinguish between the two drug names.

    - Change individual labels and carton packaging to provide better visual differentiation between the generic products for risperidone and ropinirole in order to reduce the potential for confusion. Currently, the label and packaging features (ie, similar font size and type, layout, and color) for generic ropinirole and risperidone products make the bottles look similar

    Healthcare professionals should:

    - Be sure to clearly print the drug name on written prescriptions and be sure to spell out the drug name when prescribing over the telephone.

    - Counsel patients about their prescribed medication, making sure the patient understands its purpose. Including the medical reason for the medication on the prescription may help ensure the patient gets the correct medication.

    In addition

    - Pharmacists are advised to physically separate the stocks of these two drugs on the shelf or wherever they are stored.

    - Pharmacists are advised to confirm the drug name with prescribers if the prescription is not legible or the drug name is not clearly stated

    View the full FDA Drug Safety Communication on FDA.gov